---
document_datetime: 2024-06-28 13:54:30
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/mepsevii-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: mepsevii-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.5097181
conversion_datetime: 2025-12-27 13:13:55.430026
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Mepsevii

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0040/G            | This was an application for a group of variations. B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits B.II.d.2.a - Change in test procedure for the finished | 26/06/2024                          |                                             | Annex II and PL                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | procedure A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)   |            |            |                                  |                                                                                                                                                                                                                                                                        |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10709 /202311 | Periodic Safety Update EU Single assessment - vestronidase alfa                                                                                                                                                                                                                                                                          | 13/06/2024 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                      |
| IB/0037             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                         | 08/01/2024 | n/a        |                                  |                                                                                                                                                                                                                                                                        |
| S/0036              | Annual re-assessment.                                                                                                                                                                                                                                                                                                                    | 09/11/2023 | n/a        |                                  |                                                                                                                                                                                                                                                                        |
| IB/0035             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                             | 22/09/2023 | n/a        |                                  |                                                                                                                                                                                                                                                                        |
| R/0033              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                  | 25/05/2023 | 28/07/2023 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Mepsevii in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |

<div style=\"page-break-after: always\"></div>

| PSUSA/10709 /202211   | Periodic Safety Update EU Single assessment - vestronidase alfa                                                                                                                                                                                  | 08/06/2023   | n/a        |    | PRAC Recommendation - maintenance   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----|-------------------------------------|
| S/0032                | Annual re-assessment.                                                                                                                                                                                                                            | 10/11/2022   | n/a        |    |                                     |
| IB/0031               | B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                          | 19/08/2022   | n/a        |    |                                     |
| PSUSA/10709 /202111   | Periodic Safety Update EU Single assessment - vestronidase alfa                                                                                                                                                                                  | 10/06/2022   | n/a        |    | PRAC Recommendation - maintenance   |
| IB/0030               | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                     | 03/05/2022   | n/a        |    |                                     |
| N/0028                | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                 | 21/12/2021   | 28/07/2023 | PL |                                     |
| II/0024               | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS | 02/12/2021   | n/a        |    |                                     |
| IB/0027               | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                              | 25/11/2021   | n/a        |    |                                     |
| IB/0026               | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other                                                                                                                                                    | 25/11/2021   | n/a        |    |                                     |

<div style=\"page-break-after: always\"></div>

|                     | changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                             |            |     |                                                                                                                                                                                                                                                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0025              | Annual re-assessment.                                                                                                                                                                                                                                                                                                                      | 11/11/2021 | n/a | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Mepsevii should be maintained. |
| IB/0023/G           | This was an application for a group of variations. B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product | 13/08/2021 | n/a |                                                                                                                                                                                                                                                                   |
| PSUSA/10709 /202011 | Periodic Safety Update EU Single assessment - vestronidase alfa                                                                                                                                                                                                                                                                            | 10/06/2021 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                 |
| II/0019             | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                      | 09/04/2021 | n/a |                                                                                                                                                                                                                                                                   |
| IA/0022             | B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                                 | 09/02/2021 | n/a |                                                                                                                                                                                                                                                                   |
| IB/0020             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                        | 11/01/2021 | n/a |                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| S/0017              | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                        | 10/12/2020   | n/a        |                        | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Mepsevii should be maintained.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10709 /202005 | Periodic Safety Update EU Single assessment - vestronidase alfa                                                                                                                                                                                                                                                                                                                                              | 26/11/2020   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                   |
| IAIN/0018           | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                   | 24/09/2020   | 22/09/2021 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                     |
| IB/0016/G           | This was an application for a group of variations. B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                               | 17/09/2020   | n/a        |                        |                                                                                                                                                                                                                                                                     |
| II/0013/G           | This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change | 23/07/2020   | n/a        |                        |                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                     | to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0014             | Update of sections 4.4,4.8 and 5.1 of the SmPC following the assessment of final results from study UX003-CL202, a multicenter, multinational, open- label treatment, extension of study UX003-CL301 in subjects with MPS VII, previously submitted under Article 46 of Regulation (EC) No 1901/2006; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement minor editorial changes in the Product Information. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH | 16/07/2020 | 30/09/2020 | SmPC and PL | Significant sustained reductions in urinary glycosaminoglycans (Dermatan Sulfate) were observed in patients with Mucopolysaccharidosis VII after treatment with vestronidase alfa of up to 3.6 years. Additional beneficial responses following long term treatment with vestronidase alfa was seen in some treated patients, including a sustained increase in the results of the 6-Minute Walk Test. For more information, please refer to the Summary of Product Characteristics. |
| PSUSA/10709 /201911 | Periodic Safety Update EU Single assessment - vestronidase alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 11/06/2020 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IB/0011             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 20/03/2020 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0009             | Update of sections 4.8. 5.1 and 5.2 of the SmPC following final results from paediatric study UX003- CL203, an open -label study of vestrodinase alfa enzyme replacement therapy in MPS 7 patients less than 5 years old.                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 23/01/2020 | 30/09/2020 | SmPC        | In an open-label, uncontrolled single arm study eight patients less than 5 years of age received a dose of 4 mg/kg vestronidase alfa every two weeks for 48 weeks of treatment period and additional up to 240 weeks during optional continuation period. Treatment with vestronidase alfa resulted in a rapid and                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                           |            |            |      | sustained, highly significant reduction in urinary glycosaminoglycans Dermatan Sulfate (uGAG DS) excretion with a mean percent change of -60% at Week 4 which was sustained at Week 48. Subjects who entered the Continuation Period up to Week 132 experienced further reduction in uGAG DS. A positive trend toward increased growth velocity was observed after vestronidase alfa treatment. All 3 subjects with hepatomegaly assessed by ultrasound examination at Baseline had decreased liver size to within normal range for age and sex prior to study termination.   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10709 /201905 | Periodic Safety Update EU Single assessment - vestronidase alfa                                                                                                                                                                                                                                                                                                             | 28/11/2019 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| S/0007              | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                       | 14/11/2019 | n/a        |      | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Mepsevii should be maintained.                                                                                                                                                                                                                                                                                                             |
| IAIN/0010           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                          | 05/11/2019 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0008             | Update of section 5.3 of the SmPC based on the final results from study UX003-PC010 a Developmental and Perinatal/Postnatal reproduction non-clinical study in rats including a Post-natal Behavioural/Functional Evaluation. In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 10.1. | 17/10/2019 | 30/09/2020 | SmPC | A pre-and postnatal development study in which rats were administered with UX003 once every three days beginning on Gestation Day 7 through Day 20 postpartum did not show an effect on clinical signs, growth and sexual maturation, neurobehavioral or reproductive function or any macroscopic observations in the F1 generation rats.                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                        |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/10709 /201811 | Periodic Safety Update EU Single assessment - vestronidase alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 14/06/2019 | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0005             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                              | 13/06/2019 | 16/09/2019 | SmPC, Labelling and PL |                                   |
| IAIN/0004/G         | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - | 08/04/2019 | 16/09/2019 | Annex II and PL        |                                   |
| IB/0002/G           | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS -                                                                                                                                                                                                                                                                                                                                                                                                          | 23/10/2018 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|             | quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)   |            |            |                 | Changes to   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------|
| IAIN/0001/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                              | 27/09/2018 | 16/09/2019 | Annex II and PL |              |